Clinical Advances in Diagnostics and Therapies for FGFR-Altered Cancer: Part One

Clinical Advances in Diagnostics and Therapies for FGFR-Altered Cancer: Part One

Online Course | Specialties: Family Medicine, Internal Medicine, Oncology
Released: 12/23/2020
Expires: 12/22/2021
Max Credits: 2.0
Jump to Education

Sameek Roychowdhury, MD, PhD 
Associate Professor, Department of Internal Medicine 
Division of Medical Oncology 
Medical Director, CLIA Certified Cancer Genomics Laboratory 
The Ohio State University, James Cancer Hospital and Comprehensive Cancer Center
Columbus, OH

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, NY

Lipika Goyal, MD, MPhil
Lead of Liver Cancer Research Program
Assistant Professor, Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, MA

Melanie Krook, PhD
Post-Doctoral Fellow
The Ohio State University Medical Center
Columbus, OH   

Activity Planners
Julie Blum, PhD
Director, Clinical Content
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager 
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
East Lansing, MI 

Learning Objectives
Upon completion, participants should be able to:

  • Explain the rationale to therapeutically target the FGFR signaling pathway in cancer  
  • Summarize the current and potential role of FGFR inhibitors in cancer treatment with regard to mechanism of action, efficacy, and safety 
  • Discuss future research and translational approaches on FGFR signaling from basic science to clinical studies 

Target Audience
This activity is intended for oncology professionals including physicians, physician assistants, nurse practitioners, nurses, and researchers. 
Statement of Need
Advances with technology and an increased understanding of the molecular pathways that drive oncogenesis has led to the development of novel therapies targeting fibroblast growth factor receptor (FGFR) aberrations in multiple tumor types. Several of the FGFR inhibitors are producing profound and durable responses in cancer treatment. An FGFR inhibitor recently gained FDA approval in the treatment of urothelial cancer, and other approvals are anticipated. Optimizing the clinical use of FGFR inhibitors will depend on the appropriate selection of patients who are most likely to benefit from these agents as well as the selection of the optimal FGFR-targeting agent, taking into account the selectivity of the agents, efficacy and toxicity profiles, and the design and implementation of novel strategies to overcome resistance mechanisms and further improve response rates. To that end, developing a clear understanding of the emerging research and the evolving landscape of FGFR inhibitors in various tumor types is needed to effectively optimize the use these agents in clinical practice. 

Providership Statement
Provided by Med-IQ. 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Med-IQ designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 2.0 contact hours.

Physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available. 

Medium/Method of Participation
To receive credit, read the introductory CME/CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: December 23, 2020
Expiration Date: December 22, 2021
Estimated Time to Complete This Activity: 2 hours

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  
Ghassan Abou-Alfa, MD, MBA 
Consulting fees/advisory boards: Agios, Inc., AstraZeneca, Autem Medical, Bayer HealthCare Pharmaceuticals, BeiGene, Berry Genomics, Celgene Corporation, CytomX Therapeutics, Debiopharm, Eisai Inc., Eli Lilly and Company, Flatiron, F. Hoffman-La Roche Ltd., Genentech, Gilead Science Inc., Incyte Corporation, Ipsen Group, L.A.M. Pharmaceutical Group, Loxo Oncology, Merck, MINAPHARM Pharmaceuticals, Polaris, QED Therapeutics, RedHill Biopharma, Silenseed, SillaJen, Sobi, TheraBionic, twoXAR, Incorporated, Vector Pharma, Yiviva 
Contracted research: ActaBiologica, Agios, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals, BeiGene, Berry Genomics, Bristol-Meyers Squibb, CASI Pharmaceuticals, Celgene Corporation, Exelixis, Inc., F. Hoffman-La Roche Ltd., Genentech, Halozyme, Inc., Incyte Corporation, MabVax Therapeutics, Puma Biotechnology, Inc., QED Therapuetics, SillaJen, Yiviva 
Lipika Goyal, MD, MPhil 
Consulting fees/advisory boards: Agios, Inc., Alentis Therapeutics, AstraZeneca, H3 Biomedicine, Incyte Corporation, Sirtex, Taiho Pharmaceutical Group, QED Therapeutics  
Melanie Krook, PhD, has indicated no real or apparent conflicts. 
Sameek Roychowdhury, MD, PhD 
Consulting fees/advisory boards: Incyte Corporation, Merck & Co., Inc. 

The peer reviewers and activity planners have no financial relationships to disclose. 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis. 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity. 
Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit:

Acknowledgement of Commercial Support
This activity is supported by an educational grant from QED Therapeutics.
© 2020 Med-IQ, Inc.

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • The landscape of FGFR alterations is highly diverse, and they are present at low to moderate frequencies across many tumor types; cataloging and characterizing these diverse alterations has the potential to facilitate precision medicine and benefit patients with cancer (Ornitz et al. WIREs Dev Bio 2015;4(3):215-66.)
  • Missense and truncating alterations have been found across all domains of FGFR1-3 (Krook, Silverman, Murugesan et al. ASCO 2020.)
  • The Fight202 study showed that patients with cholangiocarcinoma who were treated with pemigatinib showed a 35.5% objective response rate (Abou-Alfa et al. Lancet Oncol, Lancet Oncol. 2020 May;21(5):671-684.)
  • Treatment with futibatinib resulted in an objective response rate of 37.3% (95% CI, 25.8-50.0) and a median progression-free survival of 7.2 months (95% CI, 4.9-15.2) (Bahleda et al. Ann Oncol 2020 Oct;31(10):1405-1412.)
  • Co-mutations occurring with FGFR2 fusions and rearrangements may affect sensitivity to FGFR inhibitors (Hollebecque et al, ESMO 2019.)
  • A combination of mTOR and FGFR inhibition with INK128 and infigratinib, respectively, overcomes acquired resistance to FGFR inhibition alone (Krook et al, Molec Cancer Ther, 2020.)
  • Next-generation FGFR inhibitors and combination strategies are under investigation in advanced solid tumors (Goyal et al. Cancer Discov. 2019 Aug;9(8):1064-1079.)


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.